Phaseline

Targets › AURKB

AURKB (Aurora kinase B): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 2; Oncology; next expected readout Feb 2027.

Serine/threonine-protein kinase component of the chromosomal passenger complex (CPC), a complex that acts as a key regulator of mitosis. The CPC complex has essential functions at the centromere in ensuring correct chromosome alignment and segregation and is required for chromatin-induced microtubule stabilization and spindle assembly. (UniProt, Q96GD4)

Open in Phaseline: the race on AURKB, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Chipscreen BiosciencesIbcasertib
Serine/threonine-protein kinase Aurora-B inhibitor; Vascular endothelial growth factor receptor inhibitor
AURKB, FLT1, FLT4, KDRPhase 2Pancreatic Ductal AdenocarcinomaFeb 2027

Conditions

Pancreatic Ductal Adenocarcinoma (1)

Modalities

mixed (1)

Companies

Chipscreen Biosciences (1)

Related targets

FLT1 (1) FLT4 (1) KDR (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.